Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “17p Deletion”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Testing effectiveness (Phase 2)Study completedNCT01392079
What this trial is testing

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

Who this might be right for
Chronic Lymphocytic Leukemia
University of Ulm 135
Post-approval studies (Phase 4)Study completedNCT03190330
What this trial is testing

Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell
Johnson & Johnson Private Limited 75
Testing effectiveness (Phase 2)Ended earlyNCT01465334
What this trial is testing

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Who this might be right for
CLLSLL
Dana-Farber Cancer Institute 30
Testing effectiveness (Phase 2)Study completedNCT01889186
What this trial is testing

The Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Who this might be right for
Chronic Lymphocytic Leukemia17p DeletionCancer of the Blood and Bone Marrow
AbbVie 158
Large-scale testing (Phase 3)Study completedNCT02756611
What this trial is testing

Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic Leukemia
AbbVie 258
Testing effectiveness (Phase 2)Study completedNCT01745640
What this trial is testing

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Who this might be right for
Multiple Myeloma
University Hospital, Lille 63
Early research (Phase 1)Study completedNCT00772486
What this trial is testing

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

Who this might be right for
Chronic Lymphocytic Leukemia
Memgen, LLC 13
Testing effectiveness (Phase 2)Study completedNCT02633059
What this trial is testing

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Loss of Chromosome 17pRecurrent Plasma Cell Myeloma
Mayo Clinic 33
Large-scale testing (Phase 3)Study completedNCT02980731
What this trial is testing

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)
AbbVie 210
Not applicableUnknownNCT04008888
What this trial is testing

A Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaPlasma Cell LeukemiaExtramedullary Plasmacytoma+6 more
Institute of Hematology & Blood Diseases Hospital, China 50
Testing effectiveness (Phase 2)Study completedNCT02337829
What this trial is testing

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Acerta Pharma BV 48
Large-scale testing (Phase 3)Study completedNCT03406156
What this trial is testing

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie 120
Testing effectiveness (Phase 2)Study completedNCT01744691
What this trial is testing

Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Who this might be right for
Chronic Lymphocytic Leukemia With 17p DeletionSmall Lymphocytic Lymphoma With 17p Deletion
Pharmacyclics LLC. 145
Testing effectiveness (Phase 2)WithdrawnNCT03943342
What this trial is testing

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Who this might be right for
Chronic Lymphocytic LeukemiaLoss of Chromosome 17p
Kerry Rogers
Testing effectiveness (Phase 2)Study completedNCT01527045
What this trial is testing

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Who this might be right for
Aggressive Non-Hodgkin LymphomaBlasts Under 5 Percent of Bone Marrow Nucleated CellsChronic Lymphocytic Leukemia+18 more
Fred Hutchinson Cancer Center 47
Testing effectiveness (Phase 2)Study completedNCT03204188
What this trial is testing

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Who this might be right for
B-Cell Chronic Lymphocytic LeukemiaB-Lymphocytic Leukemia, ChronicChronic Lymphocytic Leukemia+6 more
National Heart, Lung, and Blood Institute (NHLBI) 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04124497
What this trial is testing

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaDeletion 17P Syndrome
Fondazione EMN Italy Onlus 45
Testing effectiveness (Phase 2)Study completedNCT02420912
What this trial is testing

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Who this might be right for
Loss of Chromosome 17pRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma+3 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT02758665
What this trial is testing

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Who this might be right for
Leukemia, Lymphocytic, Chronic
University of Ulm 41
Testing effectiveness (Phase 2)Study completedNCT03700450
What this trial is testing

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf 37
Load More Results